** Shares of consumer healthcare co Kenvue KVUE.N fall ~2% to $20.33 premarket
** Co forecasts 2025 adjusted profit below estimates hit by a stronger dollar and weak demand for its cough and cold products
** Co forecasts flat to 2% growth in 2025 adjusted EPS, compared with $1.14 it earned in 2024
** Analysts expect earnings to grow 5.6% this year, or to $1.21 per share, according to estimates compiled by LSEG
** Reports Q4 sales of $3.66 billion slightly missing estimates of $3.77 billion, hit by low incidences of cold, cough and flu
** Stock fell over 20% since its stock market debut in May 2023
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。